Here are five things to know.
1. Synergy’s proprietary GI platform is based on uroguanylin, a naturally occurring human GI peptide that supports normal bowel function.
2. The company’s proprietary platform includes Trulance, a once-daily tablet approved for adults with chronic idiopathic constipation and IBS with constipation.
3. Trulance (plecanatide) is structurally identical to uroguanylin with the exception of one amino acid. Trulance is contraindicated in patients less than six years old.
4. Synergy is currently developing dolcanatide for ulcerative colitis.
5. Synergy became a public company in July 2008 and is currently listed on NASDAQ.
More articles on gastroenterology:
GI leader to know: Dr. Walter Hassig of Digestive Health Specialists
Olympus implementing InterSystems HealthShare to facilitate image sharing — 3 insights
5 things to know about EndoGastric Solutions
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
